Information Provided By:
Fly News Breaks for May 27, 2016
TTNP
May 27, 2016 | 08:16 EDT
Roth Capital analyst Scott Henry says Titan Pharmaceuticals has received approval for its six-month Probuphine implant for the treatment of opioid addiction, which removes a "key risk" from the investment thesis. Probuphine will be sold by Braeburn with Titan receiving about 17% royalty, the analyst tells investors in a research note. Henry reiterates a Buy rating on Titan's stock and raised his price target on the shares to $10 from $7.75.
News For TTNP From the Last 2 Days
There are no results for your query TTNP